Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab
Background: Omalizumab, a monoclonal anti-IgE antibody, is currently indicated for the treatment of moderate-to-severe allergic asthma. To measure active IgE levels in sera from patients treated with omalizumab, the IgE subfraction in complex with omalizumab should be eliminated from total IgE, and...
Main Authors: | Reiko Ito, Yasuhiro Gon, Satoshi Nunomura, Ryo Atsuta, Norihiro Harada, Tomohiro Hattori, Shuichiro Maruoka, Yoshimichi Okayama, Chisei Ra, Shu Hashimoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-01-01
|
Series: | Allergology International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015300824 |
Similar Items
-
Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
by: S. Morteza Seyed Jafari, et al.
Published: (2019-08-01) -
Serum free IgE guided dose reduction of omalizumab: a case report
by: Yasuhiro Gon, et al.
Published: (2017-08-01) -
The pharmacological mechanisms of omalizumab in patients with very high IgE levels—Clues from studies on atopic dermatitis
by: Tse Wen Chang, et al.
Published: (2012-12-01) -
Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients
by: Nancy M. Abdelaty
Published: (2012-07-01) -
Regulation of IgE activity in inhalational tolerance via formation of IgG anti-IgE/IgE immune complexes
by: Sonali J. Bracken, et al.
Published: (2018-05-01)